DermaPro® (CL05) is an innovative drug that is derived from dichloric acid. It is applied to poorly healing and chronic wounds by a moist wound dressing.
This wound healing therapy addresses the large unmet medical need associated with difficult to heal wounds.
Mode of action
DermaPro® carries out a dual function in supporting the body with the closure of wounds by stimulating both skin growth and disinfection. This effective and rapid treatment includes wounds that are difficult to heal such as diabetic foot.
India - awaiting market authorisation
Centaur Pharmaceuticals, Mumbai, CytoTools AG’s license partner in India filed a marketing authorization application with the Indian medicines regulatory authorities in Q4 2013 for DermaPro® ( branded as Woxheal® in India) for the treatment of diabetic foot ulcers. Centaur expects to receive approval and the subsequent market launch at short notice.
A Phase III study was successfully completed in India in June 2013 and reported an excellent cure rate of over 91%. The study enrolled over 300 patients.
Europe – Phase III clinical trials completed
The European phase III trial for the treatment of diabetic foot ulcers has been completed.
Germany - Ongoing Phase II studies
Clinical trials are ongoing with DermaPro® for the treatment of venous leg ulcers.